louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05427422: Stroke Recovery Research Based on EEG-fMRI
Official title: Motor Recovery of Stroke Patients Based on Electroencephalogram-functional Magnetic Resonance Imaging
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Motor Neuropathy
Keywords: motor function recovery
ischemic stroke
EEG-fMRI
neural plasticity
Lead sponsor: Xi'an Jiaotong University
Sponsor class: OTHER
Collaborators: name: Xian Daxing Hospital
First posted: 2022-06-22
Enrollment: 147
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: AA population with motor impairment induced by first-ever stroke in a specific duration (7-14 days after stroke attack, i.e., early subacute stage) would be enrolled to investigate the mechanisms of post-stroke recovery of motor function.

Brief summary: This study is aimed to investigate the post-stroke motor recovery of patients with ischemic stroke based on their neural features extracted from EEG-fMRI data.

Detailed description: A group of patients with ischemic stroke and age/gender matched healthy controls would be enrolled in this study. Their features of neural activities based on EEG-fMRI fusion scan would be extracted to investigate the mechanisms of motor recovery after stroke. Particularly, the correlations of their features of neural networks or local activities to their motor function (defined as their Fugl-Meyer scores) at enrollment and their recovery time courses consisted of Fugl-Meyer scores in follow-up time points. Data of T1 structural, DSI fiber image and pure EEG (without MRI) would also be collected along with EEG-fMRI fusion data.

Eligibility criteria: Inclusion Criteria:

* Age above 18 and below 75 years
* Motor impairment in National Institutes of Health Stroke Scale
* 7-14 days since stroke attack
* First-ever ischemic stroke

Exclusion Criteria:

* Motor impairment induced by non-stroke aetiology
* Claustrophobia; recognition disorder
* History of other severe central nervous system diseases
* Any signs unfit for MRI/EEG scan

Primary outcomes:
measure: Fugl-Meyer scores (T0)
timeFrame: 7-14 days since stroke
measure: Fugl-Meyer scores (T1)
timeFrame: 6 weeks since stroke
measure: Fugl-Meyer scores (T2)
timeFrame: 12 weeks since stroke
measure: Fugl-Meyer scores (T3)
timeFrame: 72 weeks since stroke
Secondary outcomes:
measure: Neuroimage features based on EEG-fMRI (T0)
timeFrame: 7-14 days since stroke
measure: Neuroimage features based on EEG-fMRI (T1)
timeFrame: 6 weeks since stroke
measure: Neuroimage features based on EEG-fMRI (T2)
timeFrame: 12 weeks since stroke
measure: Neuroimage features based on EEG-fMRI (T3)
timeFrame: 72 weeks since stroke
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xi'an Daxing Hospital
state: Shanxi
Study officials:
References:
Clinical trial NCT00803322: Improving Community Based Tuberculosis Care in Ethiopia
Official title: Community Health Workers Improve Tuberculosis Case Notification and Treatment Success in Southern Ethiopia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Tuberculosis
Keywords: TB
community
community health workers
Ethiopia
identify suspects of pulmonary tuberculosis
collect sputum specimen for examination
treat smear positive cases in the community
Lead sponsor: University of Bergen
Sponsor class: OTHER
Collaborators: name: Centre for International Health, SNNP Regional health Bureau
First posted: 2008-12-05
Enrollment: 318
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: suspects of pulmonary tuberculosis in the study are. In group two suspects were identified and treated bo community health workers while in group on used the conventional health facility based tuberculosis diagnosis and treatment

Brief summary: The purpose of this study is to see if involving community health workers improves tuberculosis case finding and treatment outcome.

Detailed description: Tuberculosis suspects in the study area

Outcome smear positive tuberculosis cases identified smear positive tuberculosis cases treated

Eligibility criteria: Inclusion Criteria:

* suspects of pulmonary tuberculosis

Exclusion Criteria:

* not in the study area

Primary outcomes:
measure: smear positive tuberculosis case notification rate
timeFrame: september 2006 - setmeber 2007
Secondary outcomes:
measure: smear positive treatment success rate
timeFrame: september 2006 - April 2007
Other outcomes:
Locations:
city: Yirgalem
country: Ethiopia
facility: Dale and Wonsho districts Sidama zone, Southern Ethiopia
state: Snnpr
Study officials:
affiliation: CIH of Bergen University and RHB of SNNPRS Ethiopia
name: Daniel G Datiko, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: CIH UIB
name: Bernt Lindtjorn
role: STUDY_DIRECTOR
References:
citation: Datiko DG, Lindtjorn B. Cost and cost-effectiveness of smear-positive tuberculosis treatment by Health Extension Workers in Southern Ethiopia: a community randomized trial. PLoS One. 2010 Feb 17;5(2):e9158. doi: 10.1371/journal.pone.0009158.
citation: Datiko DG, Lindtjorn B. Health extension workers improve tuberculosis case detection and treatment success in southern Ethiopia: a community randomized trial. PLoS One. 2009;4(5):e5443. doi: 10.1371/journal.pone.0005443. Epub 2009 May 8.
Clinical trial NCT00532922: A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®
Official title: A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2007-09-21
Enrollment: 310
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Natural History, longitudinal, defined population

Brief summary: The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.


Eligibility criteria: Inclusion Criteria:

1. Provision of informed consent
2. Asthmatics who has been prescribed Symbicort according to physician's judgement
3. Usage of Symbicort should follow local prescribing information

Exclusion Criteria:

1. Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
2. No previous enrolment in the present study

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Hefel
country: China
facility: Research Site
state: Anhui
city: Fuzhou
country: China
facility: Research Site
state: Fujian
city: Guangzhou
country: China
facility: Research Site
state: Guangdong
city: Shenzhen
country: China
facility: Research Site
state: Guangdong
city: Zhengzhou
country: China
facility: Research Site
state: Henan
city: Wuhan
country: China
facility: Research Site
state: Hubei
city: Wuhan
country: China
facility: Research Site
state: Hubel
city: Nanjong
country: China
facility: Research Site
state: Jiangsu
city: Suzhou
country: China
facility: Research Site
state: Jiangsu
city: Shenyand
country: China
facility: Research Site
state: Liaoning
city: Qingdao
country: China
facility: Research Site
state: Shandong
city: Taiyuan
country: China
facility: Research Site
state: Shanxi
city: Xi'an
country: China
facility: Research Site
state: Shanxi
city: Chengdu
country: China
facility: Research Site
state: Sichuan
city: Wenzhou
country: China
facility: Research Site
state: Zhejiang
city: Beijing
country: China
facility: Research Site
city: Chongqing
country: China
facility: Research Site
city: Hangzhou
country: China
facility: Research Site
city: Shanghai
country: China
facility: Research Site
Study officials:
affiliation: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
name: Zhou Xin
role: PRINCIPAL_INVESTIGATOR
affiliation: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
name: Hong Jianguo
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06074822: Research Biobank From Neuromuscular Biopsy Residues (in the Context of Care)
Official title: Constitution of a Collection of Residues of Neuromuscular Biopsies From Patients Taken as Part of Their Health Care at the Bordeaux University Hospital for Neuromuscular Disease and Use for Research Projects
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Neuromuscular Diseases
Muscle
Nerve
Lead sponsor: University Hospital, Bordeaux
Sponsor class: OTHER
First posted: 2023-10-10
Enrollment: 500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with neuromuscular symptoms.

Brief summary: Neuromuscular diseases are rare diseases for which significant progress has been made in the context of diagnosis thanks to advances in molecular techniques, but the intimate mechanisms of lesion formation remain poorly understood. Advances in cellular and molecular biology, the development of a few animal models, such as transgenic mice, which make it possible to mimic human pathology have made it possible to better understand the physiopathology of these diseases. However, they still do so very imperfectly and incompletely, making it even more necessary than ever to study diseased human muscle tissue to find new avenues of research or to confirm results obtained by experimentation.

The purpose of this collection of tissue samples for neuro-muscular purposes is to collect such samples under the best conditions in order to promote basic and translational research on muscle diseases.

This is why the CHU de Bordeaux wishes to keep the remainders of samples taken as part of the treatment to constitute a collection of biological samples and associated data kept according to quality standards and in compliance with the regulations in force.

Detailed description: The "COLMYONEU" project is a project to collect leftover frozen neuromuscular biopsy samples from patients taken as part of their health care at the Bordeaux University Hospital for neuromuscular disease.

Its main objective is to store, under the conditions of the CRB standard, residual biological samples from patients with neuromuscular symptoms.

Eligibility criteria: Inclusion criteria

* Patients treated at Bordeaux University Hospital (neurology services, neuropediatrics), rheumatology, medical genetics for suspected neuromuscular disease.
* Men and women are affected, adults and minors.

Exclusion criteria

- no exclusion criteria

Primary outcomes:
measure: Constitution of a biocollection
timeFrame: 30 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Université Hospital, Bordeaux
Study officials:
affiliation: Université Hospital, Bordeaux
name: Marie Laure NEGRIER, Pr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00889122: Family Exergaming: A Research Study Testing a Videogame Intervention to Increase Physical Activity for Families
Official title: Family Exergaming: A Research Study Testing a Videogame Intervention to Increase Physical Activity for Families
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Keywords: Obesity
Exergames
Videogames
Prevention
Family
Dance Dance Revolution
Pedometer
Lead sponsor: MaineHealth
Sponsor class: OTHER
Collaborators: name: Robert Wood Johnson Foundation
First posted: 2009-04-28
Enrollment: 213
Sex: ALL
Minimum age (years): 9
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine if an interactive game (Dance Dance Revolution/DDR) can promote healthy physical activity for the health of all family members


Eligibility criteria: Inclusion Criteria:

* Ages 9-17
* Overweight status (BMI of 85% and above)
* Willing to come to two (2 hour) visits to MMCRI for measurements and complete surveys
* Family participation

Exclusion Criteria:

* Serious heart condition
* Photo-sensitive seizures
* Previous extensive history using DDR

Primary outcomes:
measure: Amount of physical activity
timeFrame: 14 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Scarborough
country: United States
facility: Maine Medical Center Research Institute
state: Maine
Study officials:
affiliation: MaineHealth
name: Ann Maloney, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06918522: Introduction of Sophrology and Art Therapy in Hand and Upper Limb Surgery at Lyon University Hospital
Official title: Introduction of Sophrology and Art Therapy in Hand and Upper Limb Surgery at Lyon University Hospital
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Hand and Upper Limb Trauma
Keywords: hand and upper limb trauma
sophrology
art-therapy
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2025-04-09
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients hospitalized Rehabilitation Department Pavillon T HEH Hospices Civils of Lyon- hand and upper limb surgery

Brief summary: The human and economic impact of hand and upper limb pathologies, whether acute or chronic, surgical or medical, is considerable on a national level. Hand wounds and traumas account for 1/3 of work-related accidents and their consequences. The surgical procedure and its technical quality are essential, but so is the re-education and rehabilitation phase. It is in this post-operative context that sophrology and art therapy could have their place. Literature in this precise field is non-existent. A study is therefore needed to determine the quality of life, feasibility and acceptability of these new techniques in the rehabilitation department of the Édouard Herriot Hospital's Hand and Upper Limb Surgery Unit.

Sophrology and art therapy could help to limit upper-limb sequelae by promoting confidence-building and functional participation, thus helping patients to return more quickly to an active life. Given the current state of knowledge, the hypothesis being tested is that, within the framework of an existing multi-disciplinary team, art therapy and sophrology could improve quality of life and find favorable adherence on the part of patients usually cared for in the upper limb surgery department.


Eligibility criteria: Inclusion Criteria:

* Adult (aged ≥ 18 years)
* Men and women
* Cared for in the hand and upper limb surgery department as part of emergency or scheduled activity or rehabilitation.
* Wishing to benefit from sophrology and/or art therapy in their care pathway.
* Having expressed his non-opposition

Exclusion Criteria:

* Patients under legal protection
* Any patient who does not have a sufficient command of the language to enable comprehension and expression.

Primary outcomes:
measure: Quality of life
timeFrame: Delta between before and after 16 weeks reduction post surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hospices Civils de Lyon. Rehabilitation Department Pavillon T HEH - hand and upper limb surgery
Study officials:
affiliation: Hospices Civils de Lyon. Rehabilitation Department Pavillon T HEH - hand and upper limb surgery
name: Aram GAZARIAN, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02259322: Loss of Control Eating Following Weight Loss Surgery
Official title: Treatment of Loss of Control Eating Following Bariatric Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Loss of Control Eating
Keywords: Bariatric surgery
Weight loss surgery
Behavioral weight loss treatment
Cognitive behavioral therapy
Behavioral treatment
Obesity
Morbid obesity
Binge eating
Binge eating disorder
Loss of control eating
Overeating
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2014-10-08
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will test the effectiveness of two distinct behavioral treatments for loss of control eating following bariatric surgery:

1. Behavioral Weight Loss Treatment
2. Cognitive Behavioral Therapy

These treatments will be compared to Standard-of-Care.


Eligibility criteria: Inclusion Criteria:

* Gastric bypass surgery or sleeve gastrectomy patients from Yale Bariatric/Gastrointestinal Surgery Program
* 5-8 months post-bariatric surgery
* Regular loss of control eating (once weekly during past month)
* Read English proficiently enough to read patient self-care materials and study assessments
* Available for duration of treatment plus follow-up period
* Agree to study procedures

Exclusion Criteria:

* Current enrollment in a formal exercise program
* Medical status judged by the surgeon as contraindication (rare instances of need for additional surgery or medical instability)
* Unable to ambulate
* Current medications that influence eating/weight
* Current substance dependence or other severe psychiatric disturbance (e.g., suicidality) that requires immediate treatment

Primary outcomes:
measure: Loss of Control Eating Frequency (Categorical)
timeFrame: Post-treatment (at 3 months)
measure: Loss of Control Eating Frequency (Categorical)
timeFrame: 24 month follow-up (an average of 24 months following treatment)
measure: Loss of Control Eating Frequency (Continuous)
timeFrame: Post-treatment (at 3 months)
measure: Loss of Control Eating Frequency (Continuous)
timeFrame: 24 month follow-up (an average of 24 months following treatment)
measure: Body Mass Index (BMI)
timeFrame: Post-treatment (at 3 months)
measure: Body Mass Index (BMI)
timeFrame: 24 month follow-up (an average of 24 months following treatment)
Secondary outcomes:
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale Department of Psychiatry
state: Connecticut
Study officials:
affiliation: Yale University School of Medicine, Department of Psychiatry
name: Carlos M Grilo, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lawson JL, Wiedemann AA, Carr MM, Ivezaj V, Duffy AJ, Grilo CM. Examining Sleep Quality Following Sleeve Gastrectomy Among Patients with Loss-of-Control Eating. Obes Surg. 2019 Oct;29(10):3264-3270. doi: 10.1007/s11695-019-03981-7.
Clinical trial NCT00109122: Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
Official title: A Double-Blind, Placebo-Controled, Randomized Study to Evaluate Safety, Tolerability, and Immunogenicity After 1 and 2 Doses of Zoster Vaccine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Shingles
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2005-04-25
Enrollment: 180
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine the immunity (the body's protection) against shingles after receiving two doses of an investigational vaccine or placebo (a look alike vaccine with no active ingredients).

Detailed description: The duration of treatment is 12 weeks.

Eligibility criteria: Inclusion Criteria:

* Individuals who are at least 60 years of age with a history of varicella (shingles)
* Females must have been postmenopausal.

Exclusion Criteria:

* Subjects who did not previously participate in the main study of this protocol.
* Subject had shingles since their 6 month follow-up visit in main phase of study.

Primary outcomes:
measure: VZV ELISPOT response ~6 weeks after 1 and 2 doses
timeFrame: 6 weeks after 1 and 2 doses
Secondary outcomes:
measure: To assess the safety and tolerability of the zoster vaccine. To evaluate the long-term persistence of the VZV-specific cell mediate immunity and the VZV-specific antibody response at 1 through 3 years after 2 doses of vaccine or placebo
timeFrame: 1 through 3 years after vaccination
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Vermeulen JN, Lange JM, Tyring SK, Peters PH, Nunez M, Poland G, Levin MJ, Freeman C, Chalikonda I, Li J, Smith JG, Caulfield MJ, Stek JE, Chan IS, Vessey R, Schodel FP, Annunziato PW, Schlienger K, Silber JL. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults >/=60 years of age. Vaccine. 2012 Jan 20;30(5):904-10. doi: 10.1016/j.vaccine.2011.11.096. Epub 2011 Dec 7.
Clinical trial NCT00503022: Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
Official title: A Randomized, Double-Masked, Multi-Center Phase I Study of 6 Months Duration to Assess the Safety and Tolerability of Intravenous ACZ885 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Wet Age-Related Macular Degeneration
Keywords: Wet age-related macular degeneration
ACZ885
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2007-07-18
Enrollment: 20
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates the tolerability and safety of a single intravenous infusion of ACZ885. It also explores the efficacy of the compound in central macular edema and visual acuity in patients with wet age-related macular edema.


Eligibility criteria: Inclusion criteria:

* Male or female ≥ 50 years old, with aged related macular degeneration
* Patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Exclusion criteria:

* Active intraocular inflammation or ocular infection in the study eye
* Eye disease that may result in visual loss during the study
* Chronic therapy with topical, local or systemic corticosteroids.
* Pregnant or nursing (lactating) women.

Primary outcomes:
measure: Rates of adverse events and serious adverse events, as well as changes in ophthalmic evaluations, laboratory values, electrocardiograms (ECGs) and vital signs over 6 months, following single intravenous infusion of ACZ885.
Secondary outcomes:
measure: Changes in central macular edema from Baseline up to Month 6 Changes in best-corrected visual acuity from Baseline up to Month 6
Other outcomes:
Locations:
city: Bern
country: Switzerland
city: Belfast, Northern Ireland
country: United Kingdom
city: Bristol
country: United Kingdom
city: Liverpool
country: United Kingdom
city: London
country: United Kingdom
city: Nottingham,
country: United Kingdom
city: Southampton
country: United Kingdom
city: Wolverhampton
country: United Kingdom
Study officials:
affiliation: COREC,UK
name: Novartis EH 001 862 778 8300
role: STUDY_CHAIR
References: